A Phase II, Open-Label, Multi-Center Prospective, Conversion Study in Stable Liver Transplant Patients to Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf Capsules Twice-A-Day

Trial Profile

A Phase II, Open-Label, Multi-Center Prospective, Conversion Study in Stable Liver Transplant Patients to Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf Capsules Twice-A-Day

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2017

At a glance

  • Drugs Tacrolimus (Primary) ; Tacrolimus (Primary)
  • Indications Liver transplant rejection
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Veloxis Pharmaceuticals
  • Most Recent Events

    • 08 Apr 2017 Results of a population pharmacokinetic model based on data from this and other study (NCT00496483), published in the Clinical Pharmacokinetics.
    • 03 Jul 2012 Actual patient number changed from 57 to 59 as reported by ClinicalTrials.gov.
    • 12 May 2010 Planned end date (Aug 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top